Diagnosis and management of Thygeson’s superficial punctate keratitis

Duszak, Robert S.

doi:10.1016/j.optm.2006.12.014

Cited by 7 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Topical CsA has been used in human ophthalmology for more than 40 years and evidence supports its safety and efficacy in treating various ocular surface disorders ( McCarthy et al ., 1992 ; Reinhard and Sundmache, 1999 ; Sundmacher et al ., 2001 ; Bonfioli et al ., 2005 ; Spadavecchia et al ., 2006 ; Duszak 2007 ). Ophthalmic emulsions of CsA are prepared in several different oil-based vehicles with concentrations ranging from 0.05% to 2% ( Acheampong et al ., 1998 ).…”

Section: Discussionmentioning

confidence: 99%

Topical 1% cyclosporine eyedrops for the treatment of crystalline corneal dystrophy in dogs

Crasta,

Arteaga,

et al. 2023

Open Vet J

View full text Add to dashboard Cite

Background: Crystalline corneal dystrophy (CCD) is the most common type of corneal lipidic deposition in dogs. CCD is a primary metabolic disorder of the corneal fibroblast featuring an accumulation of extracellular and intracellular lipid deposits. Corneal lipid deposits create a corneal opacity and modify the interfibrillar collagen distance, inducing light scattering. Corneal vascularization is not usually associated with the disease, but, in case of chronicity, cell death may produce inflammation and new corneal vessels are developed. To the best of the authors’ knowledge, this is the first report of a medical approach for CCD treatment in veterinary medicine. Aim: To evaluate the efficacy of topical 1% cyclosporine eyedrops (1% CsA) for the treatment of CCD in dogs. Methods: Medical records of dogs with CCD were retrospectively reviewed (2009-2020). Corneal opacification description (COD) [size (mm), depth, and opacification degree (0-3)] was evaluated at 0, 3, 6, 9, 12, and 15 months post-initial diagnosis. Dogs were classified into three groups: control group (G0), group receiving topical 1% CsA once per day (G1) and group receiving topical 1% CsA twice daily (G2). Results: Ninety-two client-owned dogs (163 eyes) of different breeds, age and gender fulfilled the inclusion criteria. When compared to G0, where the eyes significantly increased COD (p<0.001), G1 and G2 significantly decreased COD (p<0.001). In fact, the probability of reducing COD was about three times higher in G2 than in G1, being nearly the same for the right [odds ratio (OR) =2.94; 95% confidence interval (95% CI) =0.55-15.78) and left eye (OR =2.92; 95% CI =0.49-17.26). In addition, for each additional month of treatment in G2, the probability of reducing COD increased significantly (OR =1.12; 95%CI =1.00-1.26 for the right eye and OR =1.16; 95%CI =1.02-1.32 for the left eye). Conclusion: Long-term treatment with topical 1% CsA eyedrops significantly improved CCD in dogs, being the probability of reducing COD higher when applying the treatment twice daily.

show abstract

Section: Discussionmentioning

confidence: 99%

Topical 1% cyclosporine eyedrops for the treatment of crystalline corneal dystrophy in dogs

Crasta,

Arteaga,

et al. 2023

Open Vet J

View full text Add to dashboard Cite

show abstract

“…1.1 Dr Philips Thygeson described the problem first in the year 1950 and reported a case, characterized by bilateral corneal epithelial opacities with minimal or no conjunctival congestion without the stromal association attributable to virus particles. [1,2] The reason for the problem was investigated, but obtained negative proofs of virus by tissue culture and Electron microscopy. Polymerase chain reaction by material amplification also failed to demonstrate that the disease could be of viral in origin.…”

Section: Introductionmentioning

confidence: 99%

Thygeson’s Superficial Punctate Keratitis- Case Report and Review

Prabhakar¹

2013

IOSR-JDMS

View full text Add to dashboard Cite

Thygeson's superficial punctate keratitis is a subtle, chronic and bilateral condition of the corneal epithelium, typically manifests with acute exacerbations and remissions. The etiology remains uncertain, despite the possibility of viral etiology was suspected. Topical steroid administration is useful in aborting an acute phase; but steroid induced cataract and glaucoma developed on long term usage. Topical cyclosporine A was used successfully for prolonged periods with minimal ocular surface irritation. The purpose of this case study was to highlight the importance of diagnosing the problem clinically and also to report efficacy and ocular side effects of topical cyclosporine A. Twenty six year old boy presented with persistent foreign body sensation in July 2011, since one month in both the eyes. Slit lamp microscopic examination revealed bilateral, multiple and punctate corneal epithelial lesions. The lesions resolved on topical steroids but recurred after cessation of the therapy. With the daily instillation of topical cyclosporine A, recurrence was not observed in two year follow up. Although topical steroid was useful in aborting an acute phase, the disease remitted on cessation of the therapy. Topical cyclosporine A, used for two years was effective in controlling the exacerbations without discernible ocular side effects.

show abstract